Page 3,038«..1020..3,0373,0383,0393,040..3,0503,060..»

Category Archives: Transhuman News

BI280 Chapter 10 Genetic Engineering – Part 2 of 2 – Video

Posted: November 5, 2014 at 10:44 pm


BI280 Chapter 10 Genetic Engineering - Part 2 of 2

By: Heidi Bulfer

Read more:
BI280 Chapter 10 Genetic Engineering - Part 2 of 2 - Video

Posted in Genetic Engineering | Comments Off on BI280 Chapter 10 Genetic Engineering – Part 2 of 2 – Video

BI280 Chapter 10 Genetic Engineering – Part 1 of 1 – Video

Posted: at 10:44 pm


BI280 Chapter 10 Genetic Engineering - Part 1 of 1

By: Heidi Bulfer

Read the original post:
BI280 Chapter 10 Genetic Engineering - Part 1 of 1 - Video

Posted in Genetic Engineering | Comments Off on BI280 Chapter 10 Genetic Engineering – Part 1 of 1 – Video

Lies, Damn Lies And Genetic Engineering

Posted: at 10:44 pm

The big agribusiness companies have achieved regulatory capture of government agenciesbut not in the way that many people think. At the urging of industry, since the 1980s federal agencies have over-regulated genetically engineered plants, animals and microorganismsat great cost to U.S.-based R&D and, ultimately, to consumers.

Its no secret that although the Internet has vastly enriched our lives in many respects, it has downsidesless interpersonal interaction, more anonymous snarkiness, online harassment and even cyber-stalking.

The net has also made it difficult to stop or correct the promulgation of misinformation, as I have learned to my dismay: A valid observation I made to a New York Times reporter for a 2001 article on the regulation of genetic engineering has been repeatedly taken out of context and misrepresented by activists. It continues to appear anewstill out of context and misconstrued13 years later.

Here is the portion of the original article that is often quoted on anti-genetic engineering websites (such as here and here):

Even longtime Washington hands said that the control this nascent [agbiotech] industry exerted over its own regulatory destinythrough the Environmental Protection Agency, the Agriculture Department and ultimately the Food and Drug Administrationwas astonishing. In this area, the U.S. government agencies have done exactly what big agribusiness has asked them to do and told them to do, said Dr. Henry Miller, a senior research fellow at the Hoover Institution, who was responsible for biotechnology issues at the Food and Drug Administration from 1979 to 1994.

Sounds like a Eureka! moment, right? A former senior regulatorrevealing an egregious example of what economists call regulatory captureagencies that were created to act in the public interest instead advancing the interests of the industry or sector they oversee by implementing too-lenient regulation. (Economics Nobel Laureate George Stigler developed this concept.) Thats what activistsand even somejournalists who failed to do their homeworkwould have you believe.

That excerpt has been misrepresented to imply that companies applying the molecular techniques of genetic engineering to agriculture (the exemplar of which was, and is, Monsanto) wanted, and got, less regulatory scrutiny than was warranted, possibly putting consumers and the environment at risk.

Actually, my statement was intended to convey exactly the opposite, as was clear from verbiage in the article that preceded the passage quoted above:

Although the Reagan administration had been championing deregulation across multiple industries, Monsanto had a different idea: the company wanted its new technology, genetically modified food, to be governed by rules issued in Washingtonand wanted the White House to champion the idea. There were no products at the time, Leonard Guarraia, a former Monsanto executive who attended the [Vice President George H.W.] Bush meeting, recalled in a recent interview. But we bugged him for regulation. We told him that we have to be regulated.

The genetically improved varieties that had been crafted for centuries with older, less precise, less predictable techniques of genetic modification neither needed nor received any government review or imprimatur for field trials or commercialization. Butfor its new varieties crafted with state-of-the art molecular techniques, the big agribusiness companies wanted sui generis regulatory requirements that would be far in excess of what scientific considerations and the principles of sound regulation dictated. And as the Times article related, [T]he White House complied, working behind the scenes to help Monsantolong a political power with deep connections in Washingtonget the regulations that it wanted.

Read the original:
Lies, Damn Lies And Genetic Engineering

Posted in Genetic Engineering | Comments Off on Lies, Damn Lies And Genetic Engineering

Colorado, Oregon Reject GMO Labeling

Posted: at 10:44 pm

Supporters of efforts to label GMOs in foods turn out at a rally in Denverin 2013. A ballot measure that would such labels failed to pass by a wide margin Tuesday. Luke Runyon/KUNC/Harvest Public Media hide caption

Supporters of efforts to label GMOs in foods turn out at a rally in Denverin 2013. A ballot measure that would such labels failed to pass by a wide margin Tuesday.

An effort to label genetically modified foods in Colorado failed to garner enough support Tuesday. It's the latest of several state-based GMO labeling ballot measures to fail. UPDATE: A similar measure in Oregon was also defeated by a narrow margin.

Voters in Colorado resoundingly rejected the labeling of foods that contain the derivatives of genetically modified - or GMO crops, with 66 percent voting against, versus 34 percent in favor.

In Oregon the outcome was closer, with fewer than 51 percent voting against the measure. Political ad spending in Oregon was more competitive than in Colorado, where labeling opponents outspent proponents by millions of dollars.

Meanwhile, a proposal in Maui County, Hawaii, skipped the labeling debate altogether. Voters there narrowly approved a moratorium on GMO crop cultivation. The state has been a battleground between biotech firms and food activists. Some Hawaiian farmers grow a variety of papaya genetically engineered to resist a plant virus.

Polling prior to the GMO labeling vote in Colorado was scarce. Polls found Colorado's measure faced an uphill battle in the final weeks before the election. A Suffolk University poll found only 29 percent of registered voters favored the measure, while 49 percent were likely to vote against it. A Denver Post poll was even more damning. According to that poll, 59 percent were opposed to GMO labeling in Colorado, 34 percent in favor.

Colorado's Proposition 105 would've required food companies to label packaged foods with the text "produced with genetic engineering." Oregon's Measure 92 says food labels would need to include the words "genetically engineered." Many processed foods contain soybean oil, corn syrup, refined sugar and cottonseed oil. Those oils and syrups are often derived from GMO crops that farmers have adopted over the last 18 years. Few whole foods, like the ones you see in the produce aisle, are genetically engineered, though some GE varieties of sweet corn, squash and papaya are approved for sale in the U.S.

The failed measures in Colorado and Oregon follow a nationwide trend. Similar ballot questions in California and Washington state were rejected in 2012 and 2013, respectively. This summer, Vermont's governor signed the nation's first GMO labeling requirement into law. It's supposed to take effect in 2016, but a coalition of biotech firms and farmer groups have filed suit to prevent that from happening.

Groups opposed to GMO labeling poured big money into efforts to quash the ballot measures, spending more than $15 million in Colorado alone. In Oregon, opponents of labeling raised more than $18 million, making the ballot measure the most expensive issue campaign in the state's history. Most of that money came from large seed corporations like Monsanto and DuPont Pioneer, and from processed food companies like Pepsi, Land O' Lakes and Smucker's. All of that outside money opened labeling opponents up to criticism of being tied to corporate interests.

Read more:
Colorado, Oregon Reject GMO Labeling

Posted in Genetic Engineering | Comments Off on Colorado, Oregon Reject GMO Labeling

Colorado Prop 105: GMO food fight won by opponents of labeling

Posted: at 10:44 pm

Election judges check signatures on ballots at the Denver Election Headquarters in downtown Denver, November 04, 2014. Closes races in Colorado are drawing a last minute rush to vote on election day. (RJ Sangosti, The Denver Post)

Voters dished up rejection for Proposition 105, labeling of genetically modified foods, with 35 percent of votes counted.

The measure would have required labels for GMOs foods produced with genetic engineering or containing genetically modified ingredients. More than 68 percent of voters said no to labeling.

Most processed foods sold in America include GMO ingredients such as corn syrup, corn oil, soybean crops and sugar.

Supporters of GMO labeling, such as Right to Know Colorado, Whole Foods and Natural Grocers, said it would give consumers a choice about what they serve their families.

It's a label, not a ban, alerting people to an unnatural manipulation of food, they argued.

Opponents of Prop 105 said the measure would create new costs and red tape for farmers, food manufacturers and grocery stores and consequently would run up grocery bills and cost taxpayers millions for the government oversight.

View post:
Colorado Prop 105: GMO food fight won by opponents of labeling

Posted in Genetic Engineering | Comments Off on Colorado Prop 105: GMO food fight won by opponents of labeling

Environmental Carcinogens Leave Distinctive Genetic Imprints in Tumors

Posted: at 10:44 pm

Genetically engineering tumors in mice, a technique that has dominated cancer research for decades, may not replicate important features of cancers caused by exposure to environmental carcinogens, according to a new study led by UC San Francisco scientists. In addition to pointing the way to better understanding of environmental causes of cancer, the findings may help explain why many patients do not benefit from, or develop resistance to, targeted drug therapies.

In the new research, reported November 2, 2014 in the advance online edition of Nature, a team led by UCSF graduate student Peter M.K. Westcott found that chemically induced lung tumors in mice carry hundreds of point mutationsdeleterious alterations of single letters in the genomethat are not present in tumors induced by genetic engineering. The researchers demonstrated that chemically induced tumors display a starkly different mutational landscape even when chemicals cause a tumor-initiating mutation that is identical to that created by direct genetic manipulation.

Since the 1980s, when genetic engineering came along, the mouse model community has been working on genetically engineered canceryou put a gene in or take a gene out, and you get a tumor, said Allan Balmain, PhD, the Barbara Bass Bakar Distinguished Professor in Cancer Genetics at UCSF and senior author of the study. But its only now that were beginning to analyze what has happened between that first engineered change and the ultimate development of an aggressive tumor.

The new work made use of next-generation sequencing (NGS) technology, which allows researchers to analyze the genomic sequence of tumors or of normal tissue letter-by-letter. For the Nature study, the group used a form of NGS known as whole-exome sequencing, which comprehensively analyzes the portion of the genome that contains the code for producing proteins.

The findings dovetail well with those from NGS-based studies of human tumors, such as The Cancer Genome Atlas (TCGA) initiative spearheaded by the National Cancer Institute and National Human Genome Research Institute, which have revealed mutational signatures, some of which can be definitively tied to environmental exposures. For example, distinctive patterns of point mutations are now known to differentiate lung cancer in smokers from that affecting non-smokers.

The results are also consistent with observations that tumors arising in human organs that are most directly exposed to environmental carcinogensthe skin, gastrointestinal system, and lungsare more prone to point mutations than more protected organs such as the brain, breast, and prostate gland.

We humans smoke cigarettes, drink alcohol, and spend too much time in the sun, all of which cause us to accumulate point mutations that are major determinants of the behavior of tumors, especially of how a tumor responds to therapy, said Balmain, co-leader of the Cancer Genetics Program at UCSFs Helen Diller Family Comprehensive Cancer Center. All this heterogeneity is being missed with genetically engineered tumors, because they dont reflect these environmental effects.

But only a very small number of the 25 mutational signatures revealed by NGS in human tumors so far have been convincingly tied to environmental exposures, Balmain said, so there is much to learn. Other very unusual, very specific signatures have been seen in human studies that remain obscure. Theyre like a smoking gunwe know theyre caused by something environmental, but were not sure what.

To date most epidemiological research on environmental causes of cancer has relied on patients and families to recall and document dietary habits, alcohol and tobacco use, or occupational exposures, and the rise of NGS offers an opportunity to approach these questions more rigorously, said Balmain.

To that end, Balmains research group is embarking on a collaboration with the National Institute of Environmental Health Sciences, which maintains a collection of thousands of mouse and rat tumors caused by exposure to suspected human carcinogens. Through NGS analyses of that collection, the research team hopes to find mutational signatures that can be correlated with those seen in human cancer.

See the original post here:
Environmental Carcinogens Leave Distinctive Genetic Imprints in Tumors

Posted in Genetic Engineering | Comments Off on Environmental Carcinogens Leave Distinctive Genetic Imprints in Tumors

New e-Incubator enables real-time imaging of bioengineered tissues in controlled unit

Posted: at 10:44 pm

PUBLIC RELEASE DATE:

5-Nov-2014

Contact: Kathryn Ryan kryan@liebertpub.com 914-740-2100 Mary Ann Liebert, Inc./Genetic Engineering News @LiebertOnline

"New Rochelle, NY, November 5, 2014The e-incubator, an innovative miniature incubator that is compatible with magnetic resonance imaging (MRI), enables scientists to grow tissue-engineered constructs under controlled conditions and to study their growth and development in real-time without risk of contamination or damage. Offering the potential to test engineered tissues before human transplantation, increase the success rate of implantation, and accelerate the translation of tissue engineering methods from the lab to the clinic, the novel e-incubator is described in an article in Tissue Engineering, Part C, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers. The article is available free on the Tissue Engineering website at http://online.liebertpub.com/doi/full/10.1089/ten.tec.2014.0273 until December 5, 2014."

"In the article "The e-Incubator: A Magnetic Resonance Imaging-Compatible Mini Incubator" , Shadi Othman, PhD, Karin Wartella, PhD, Vahid Khalilzad Sharghi, and Huihui Xu, PhD, University of Nebraska-Lincoln, present the results of a validation study using the device to culture tissue-engineered bone constructs for 4 weeks. The e-incubator is a standalone unit that automatically detects and regulates internal conditions such as temperature, carbon dioxide levels, and pH via a microcontroller. It performs media exchange to feed the cultures and remove waste products. The current design is compatible with MRI to monitor the constructs without removing them from the incubator. With proper adjustments, compatibility with other imaging technologies including computed tomography (CT) and optical imaging is also possible."

""Calibratable, hands-free tissue development environments are becoming increasingly important for the engineering of implantable tissues," says Tissue Engineering Co-Editor-in-Chief Peter C. Johnson, MD, Vice President, Research and Development, Avery Dennison Medical Solutions of Chicago, IL and President and CEO, Scintellix, LLC, Raleigh, NC. "In this new development, noninvasive imaging modalities are added to the spectrum of sensing and environmental capabilities that heretofore have included temperature, humidity, light, physical force, and electromagnetism. This represents a solid advance for the field.""

###

About the Journal

"Tissue Engineering is an authoritative peer-reviewed journal published online with Open Access options and in print in three parts: Part A, the flagship, published 24 times per year; Part B: Reviews, published bimonthly; and Part C: Methods, published 12 times per year. Led by Co-Editors-In-Chief Antonios Mikos, PhD, Louis Calder Professor at Rice University, Houston, TX, and Peter C. Johnson, MD, Vice President, Research and Development, Avery Dennison Medical Solutions of Chicago, IL and President and CEO, Scintellix, LLC, Raleigh, NC, the Journal brings together scientific and medical experts in the fields of biomedical engineering, material science, molecular and cellular biology, and genetic engineering. Tissue Engineering is the official journal of the Tissue Engineering & Regenerative Medicine International Society (TERMIS). Complete tables of content and a sample issue may be viewed on at the Tissue Engineering website at http://www.liebertpub.com/ten. "

About the Publisher

Read more:
New e-Incubator enables real-time imaging of bioengineered tissues in controlled unit

Posted in Genetic Engineering | Comments Off on New e-Incubator enables real-time imaging of bioengineered tissues in controlled unit

UAB Researcher Has Key Role in Massive Non-Hodgkin Lymphoma Study

Posted: at 10:44 pm

Contact Information

Available for logged-in reporters only

Newswise BIRMINGHAM, Ala. In 2001, Christine Skibola, Ph.D., now a professor of epidemiology at the University of Alabama at Birmingham School of Public Health, joined forces with a small group seeking a large goal discovery of genetic and environmental links to the white blood cell tumors that collectively are called lymphomas.

This has now resulted in the largest epidemiology and genetic studies of non-Hodgkin lymphoma (NHL) ever conducted. Thus far, these studies have culminated into four genetics papers published in Nature Genetics, American Journal of Human Genetics and Nature Communications, and an entire monograph in the Journal of the National Cancer Institute Monographs comprising 13 papers on environmental and medical risk factors found to be associated with various lymphoma subtypes. More papers are on the way.

This sort of research is huge in scale. The hundreds of investigators involved did risk factor analysis and genome-wide association studies on more than 17,400 NHL cases and 23,000 matched controls from North America, Europe and Australia. Two recent Skibola papers, for example, included 140 different authors at 82 different universities, institutes or hospitals that were located in 16 U.S. states and 18 foreign countries.

This is what it takes now to get the large power to detect true associations in most cases, Skibola said.

Those results finding links to personal and family histories, or associations with individual genetic markers set the path for future research and future possible treatments.

Consider the stark difference in risk profiles discovered by Skibola and others for two of the most common types of NHL diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL).

On the one hand, when researchers looked at risk factors related to medical history, lifestyle, family history and occupation, the DLBCL patients had numerous significant risks. These included being obese as a young adult, having a history of any one of a number of autoimmune diseases and a family history of a blood cancer. Other factors, such as allergic conditions, a history of alcohol consumption or a previous blood transfusion for men, and hormone replacement therapy or oral contraceptive use for women, gave some protection from DLBCL. In contrast, only a few, modest epidemiology risk factors were found for FL.

On the other hand, when researchers looked at risk factors associated with genetic changes, the tables were reversed: FL had a number of profound genetic risk factors and DLBCL had much less.

Continued here:
UAB Researcher Has Key Role in Massive Non-Hodgkin Lymphoma Study

Posted in Human Genetics | Comments Off on UAB Researcher Has Key Role in Massive Non-Hodgkin Lymphoma Study

Ottawa hospital challenges patent on human genes (with video)

Posted: at 10:44 pm

Saying no one should be able to patent human DNA, the Childrens Hospital of Eastern Ontario is asking the Federal Court to declare patents on genes linked to an inherited heart condition called Long QT Syndrome invalid.

The potential implications of the legal challenge, the first of its kind in Canada, are huge.

If the court agrees with the hospitals argument that the patents should never have been issued in the first place, there would be a ripple effect on other such patents and pending patents on human DNA. TheU.S. Supreme Court has already made a similar ruling invalidating patents on human DNA.

Our position is very straightforward, hospital CEO Alex Munter told a press conference held just after court documents were filed in Toronto on Monday. No one should be able to patent human DNA, it would be like patenting air or water. Doing so, he said, has a negative impact on the future of medicine, on patients access to their own genetic information and on the quality of care.

CHEO is taking on the first Canadian case because it is a major centre for genetics research and clinical applications. Patents on genetic materials, such as the ones that touch on Long QT Syndrome, Muntersaid, are a major obstacle to research and treatment of genetic diseases. The patents in question, five of them, are held by the University of Utah, Genzyme Genetics and Yale University.

Our genetics leadership really is at the leading edge in Canada of moving us toward that era of personalized medicine that everyone is talking about, Munter said. But patents on human DNA, he added, have been identified as an obstacle that will stand in the way of delivering on that promised future.

Long QT Syndrome affects an estimated one in 2,500 newborns. It can lead to life-threatening arrhythmias and is the cause of a significant number of sudden deaths in young adults, sometimes seen in deaths of young athletes playing sports. Sometimes symptoms such as fainting spells during exercise can help doctors diagnose and treat a patient, but in some cases, the first symptom of the syndrome is sudden death, said Dr. Gail Graham, who heads the hospitals department of genetics.

The syndrome is fully treatable with medications once diagnosed, but it can be tricky to diagnose using electrocardiogram alone, Graham said. Genetic testing along with ECG can come up with a conclusive diagnosis.

CHEO was set to become one of Ontarios testing centres for the syndrome but the province received a cease-and-desist order from the holder of the patents that are linked to the disease. Now, because of the patents surrounding the genes involved in the disease, testing must be done in the U.S. at a cost of about $4,500 to $4,800 a patient, said Graham, compared to between $1,500 and $2, 000 if it could be done here. Being able to test here, she said, would save the Ontario health system $200,000 a year. If genes continue to be patented, she said, the cost to the provincial health system will rise into the millions every year.

CHEO is in the final stages of verifying a new genetic test that wouldsimultaneously sequence all of the thousands of genes in an individual that been linked to human genetic diseases. It is something that couldnt even be imagined five years ago, said Graham, chief of the hospitals department of genetics. But such a test creates a potential nightmare scenario for patients with undetected Long QT syndrome, she said. If thetest done on a patient incidentally turned up the genetic mutations for Long QTsyndrome, she said, lab scientistswould be prevented by law from passing that information along to the physician treating the patient, meaning a potentially fatal condition would go untreated.

Excerpt from:
Ottawa hospital challenges patent on human genes (with video)

Posted in Human Genetics | Comments Off on Ottawa hospital challenges patent on human genes (with video)

SHILINGI YANGU – SHIDA MBILI feat. DNA [OFFICIAL VIDEO] – Video

Posted: at 10:44 pm


SHILINGI YANGU - SHIDA MBILI feat. DNA [OFFICIAL VIDEO]
Grandpa Government/Grandpa Records Presents SHILINGI YANGU - SHIDA MBILI feat. DNA [OFFICIAL VIDEO] Visita and KenRazy have now merged as a duo under the name SHIDA MBILI and have ...

By: GRAND PA GOVERNMENT

Read the rest here:
SHILINGI YANGU - SHIDA MBILI feat. DNA [OFFICIAL VIDEO] - Video

Posted in DNA | Comments Off on SHILINGI YANGU – SHIDA MBILI feat. DNA [OFFICIAL VIDEO] – Video

Page 3,038«..1020..3,0373,0383,0393,040..3,0503,060..»